Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Pleural effusion induced by bromocriptine].

E Diot1, P Diot, A Le Rolland

  • 1Service de Médecine B, CHU Bretonneau, Tours.

Revue Des Maladies Respiratoires
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Job-exposure matrix (JEM) validity on crystalline silica among systemic sclerosis patients.

Occupational medicine (Oxford, England)·2025
Same author

Large-vessel involvement in ANCA-associated vasculitis: A multicenter case-control study.

Seminars in arthritis and rheumatism·2024
Same author

[Popliteal pain of unusual cause].

La Revue de medecine interne·2023
Same author

[Characteristics of patients with connective tissue disease-associated pulmonary arterial hypertension treated with prostanoids: A multicenter retrospective study].

La Revue de medecine interne·2021
Same author

Lack of essential medical resources leaves Africa breathless.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

Giant cell arteritis-related aortitis with positive or negative temporal artery biopsy: a French multicentre study.

Scandinavian journal of rheumatology·2019
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Bromocriptine, used for Parkinson's disease, can cause rare pleural effusions. Discontinuation of this ergot derivative led to rapid patient recovery, highlighting potential respiratory risks.

Area of Science:

  • Pulmonology
  • Neurology
  • Pharmacology

Background:

  • Bromocriptine, an ergot derivative, is prescribed for Parkinson's disease.
  • High-dose bromocriptine therapy is associated with potential pleuro-pulmonary complications.
  • Pleuro-pulmonary fibrosis is the most commonly reported respiratory adverse effect.

Observation:

  • A 72-year-old patient developed unilateral then bilateral pleural effusion during bromocriptine treatment for Parkinson's disease.
  • The pleural effusion was characterized as a transudate with no clear etiology.
  • The patient's condition improved rapidly after discontinuing bromocriptine therapy.

Findings:

  • Isolated pleural effusions are rare complications of bromocriptine, often presenting as exudates.
  • The pathogenesis may involve toxic fibrogenesis, vascular effects, or immunological responses.

Related Experiment Videos

  • The actual frequency of bromocriptine-induced pleural effusions might be underestimated.

    • Implications:

    • This case highlights the importance of considering bromocriptine as a potential cause of pleural effusion.
    • Close monitoring for respiratory symptoms in patients on bromocriptine is crucial.
    • Further research is needed to understand the mechanisms and prevalence of these drug-induced lung conditions.